Business Wire

TSURUMI-BREWING

30.11.2015 15:01:49 CET | Business Wire | Press release

Share
Sales to Begin of Tsurumi Brewing's SUSHI SAKE—A Sake Expressly for Sushi, Japan's Culinary Gift to the World

Founded in 1873, Tsurumi Shuzou Co., Ltd. (hereinafter, Tsurumi Brewing ) have developed SUSHI SAKE Kamitsuru Junmai Daiginjo (junmai means it is made with only rice products and no added alcohol, and daiginjo refers to the fact that the rice has been milled to fifty percent or less of its weight during the process), based on the concept of having a Japanese sake to go with sushi, in conjunction with the boom we are currently seeing in sake popularity outside of Japan. Sales have begun in November of 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151130005179/en/

Product info: http://www.tsurumi-jp.com/sushi_sake/en

Priced at ¥12,000 per bottle, SUSHI SAKE Kamitsuru Junmai Daiginjo, a Sake for Sushi

Tsurumi Brewing, a company that produces and sells sake, began sales of SUSHI SAKE Kamitsuru Junmai Daiginjo in November, working from the notion that sake could serve to improve the wonderful taste of sushi, beloved world-wide, and representative of Japan’s food culture.

We designed SUSHI SAKE to hold back the raw odors unique to the fish used in sushi on your palette while paying particular attention to the balance for the earthier, umami flavors. By offering a crisp finishing tone, you will find it goes very well with sushi by preparing you for the next bite.

Developed by a Venerable Japanese Sake Brewer

Development of SUSHI SAKE occurred at Tsurumi Brewing, an esteemed, established sake brewery in Aichi Prefecture. Tsurumi Brewing began its history in 1873 when founder Teizo Tsurumi, who had been working with dyed goods, opened a sake brewery.

We maintain the traditional methods of production that have been handed down in the Tsushima area, striving to protect the merits of production by hand in the process. At the same time, we are also working to harmonize these methods with more modern systems of quality control and ingenuity, as we strive to create even better sake, and drawing out the depths of flavor inherent in the rice to impart a truly rich taste.

Completed After Trial and Error Under the Tutelage of the Master of a Long-established Restaurant, Founded in 1934

When it came to put the finishing touches on SUSHI SAKE, we turned to the advice of a respected, long-established restaurant, having many fans across Japan. This, we knew, would be critical in our process for the sixth generation of the Tsurumi family who currently operates the company that was founded in 1873.

Using only Yamadanishiki rice, we mill it down to forty percent of its weight. We draw water from an underground source of the Kiso River. Fermentation of the sake occurs at the optimal low temperatures found during the peak of winter, and it is the skill and dedication of the chief brewer, applied slowly over time, that results in the highest quality sake. You will enjoy a subtly rich taste.

Plans to Expand Sales from Shanghai and Hong Kong to Paris and New York

At present, SUSHI SAKE is available at the most established restaurants and department stores in Japan, but starting in December, there will be tastings planned, along with Japanese food, at restaurants in Italy. Moving forward, we plan to expand exports to Shanghai, Hong Kong, Paris, and New York. We will also be increasing availability at restaurants within Japan, as well as sales at department stores and online. Other varieties of SUSHI SAKE in addition to Junmai Daiginjo will be available for sale as well, including Daiginjo, Junmai Ginjo, Ginjo, and Junmai (ginjo refers to the fact that the rice has been milled to 60% of its weight or less).

 

Product Facts

Name  

:

  SUSHI SAKE Kamitsuru Junmai Daiginjo
Price

:

¥12,000 (pre-tax)
Volume

:

1,800 ml
Ingredients

:

Rice, rice malt
Percent alcohol

:

15.5%
Rice used

:

100% Yamadanishiki
Milling degree

:

40%
 

Corporate Overview

Name  

:

  Tsurumi Shuzou Co., Ltd.
Address

:

46 Asahi, Hyaku-cho, Tsushima City, Aichi Prefecture
Representative

:

Masahito Tsurumi
Capitalization

:

¥10 million
Established

:

1873
Incorporation

:

December 1949
Business

:

Production, wholesaling, and retailing of sake, mirin, liqueurs, shochu products, fruit wines, fortified wines, miscellaneous liquors, spirits, beer, and vinegar
Website

:

http://www.tsurumi-jp.com/sushi_sake/en

Contact:

TSURUMI SHUZOU Co., Ltd.
Masahito Tsurumi, +81-567-31-1141
tsurumi@tsurumi-jp.com
Fax: +81-567-32-0586

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye